MAP2K1 and breast carcinoma: Our study, however, is quite distinct from the study by the Eastman laboratory, which did not use hormonal therapy, or identify the key role of the proapoptotic BimEL protein in mediating death in response to MEK1 blockade in hormonally treated breast cancer cells.